For instance, PD-L1-positive exosomes serve as indicators of immune checkpoint activity and predictors of patient response to immunotherapy [98,137], while mutated EGFR-carrying exosomes enable the tracking of resistance to targeted therapies in NSCLC [136,138]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.